Objective. Recent studies have demonstrated that there is an inverse relationship between lymphatic egress and inflammatory arthritis in affected joints. As a model, tumor necrosis factor (TNF)-transgenic mice develop advanced arthritis following draining lymph node (LN) collapse, and loss of lymphatic contractions downstream of inflamed joints. It is unknown if these lymphatic deficits are reversible. This study was undertaken to test the hypothesis that anti-TNF therapy reduces advanced erosive inflammatory arthritis, associated with restoration of lymphatic contractions, repair of damaged lymphatic vessels, and evidence of increased monocyte egress.
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Objective. Recent studies have demonstrated that there is an inverse relationship between lymphatic egress and inflammatory arthritis in affected joints. As a model, tumor necrosis factor (TNF)-transgenic mice develop advanced arthritis following draining lymph node (LN) collapse, and loss of lymphatic contractions downstream of inflamed joints. It is unknown if these lymphatic deficits are reversible. This study was undertaken to test the hypothesis that anti-TNF therapy reduces advanced erosive inflammatory arthritis, associated with restoration of lymphatic contractions, repair of damaged lymphatic vessels, and evidence of increased monocyte egress.
Methods. TNF-transgenic mice with advanced arthritis and collapsed popliteal LNs were treated with anti-TNF monoclonal antibody (10 mg/kg weekly) or placebo for 6 weeks, and effects on knee synovitis, lymphatic vessel ultrastructure and function, and popliteal LN cellularity were assessed by ultrasound, histology, transmission electron microscopy (TEM), near-infrared indocyanine green imaging, and flow cytometry.
Results. Anti-TNF therapy significantly decreased synovitis (~5-fold; P < 0.05 versus placebo), restored lymphatic contractions, and significantly increased the number of popliteal LN monocyte/macrophages (~2-fold; P < 0.05 versus placebo). TEM demonstrated large activated macrophages attached to damaged lymphatic endothelium in mice with early arthritis, extensively damaged lymphatic vessels in placebo-treated mice with advanced arthritis, and rolling leukocytes in repaired lymphatic vessels in mice responsive to anti-TNF therapy.
Conclusion. These findings support the concept that anti-TNF therapy ameliorates erosive inflammatory arthritis, in part via restoration of lymphatic vessel contractions and potential enhancement of inflammatory cell egress.
Despite the establishment of tumor necrosis factor (TNF) inhibitors as standard of care for rheumatoid arthritis (RA), the mechanisms by which they ameliorate synovitis in inflamed joints remain incompletely understood. Specifically, how an anti-TNF agent reduces synovial macrophage numbers independent of apoptosis (1,2), and alters monocyte influx into the synovium (3) , remains an open question. One possible explanation is that TNF inhibition increases the efflux of monocyte/macrophages from the synovium, which is supported by studies demonstrating that anti-TNF increases lymphangiogenesis in murine inflammatory arthritis and in RA patients (4, 5) . However, anti-TNF-induced cellular egress from joints during flare has yet to be formally demonstrated.
Previously, we demonstrated that progression of arthritis in the knee joints of TNF-transgenic mice is paralleled by dramatic changes in the draining lymph nodes (LNs) (6) (7) (8) . Those longitudinal imaging studies combining contrast-enhanced magnetic resonance imaging (CE-MRI) of the synovium and popliteal LNs (6) with quantitation of lymphatic drainage via near-infrared (NIR) imaging of an injected dye (indocyanine green [ICG] ) (9) demonstrated that prior to detectable synovial hyperplasia in the knee, the adjacent popliteal LN expands due to increased lymphangiogenesis, lymphatic fluid accumulation, CD11b1 macrophage infiltration, and the expansion of a unique subset of CD231/CD21 high B cells in inflamed nodes (5, (9) (10) (11) (12) (13) (14) . This asymptomatic "expansion" phase is followed by a sudden "collapse" of the popliteal LN, which is identified by CE-MRI or power Doppler imaging of the popliteal LN (6, 15) . This collapse, which occurs at variable time intervals in ;80% of TNF-transgenic mice, is associated with the translocation of CD231/CD21 high B cells in inflamed nodes from the follicles to lymphatic vessel endothelial hyaluronan receptor 1-positive lymphatic vessels of the paracortical sinuses, and a reduction in LN volume and increase in popliteal LN fluid pressure (6, 8, 16) . Thereafter, lymphatic drainage declines significantly due to loss of intrisic lymphatic contractions and passive flow (7, 8, 10, 13) .
It has also been demonstrated that B cell depletion therapy with anti-CD20 antibodies ameliorated knee flare afferent to collapsed popliteal LNs by clearing the LN sinuses and restoring passive lymphatic flow in the absence of lymphatic contractions (8) . However, whether agents that target the underlying etiology of inflammatory arthritis can restore lymphatic vessel contractions during the collapsed phase of the disease remains unknown. To this end, we evaluated the effects of anti-TNF treatment on advanced knee arthritis in TNF-transgenic mice to determine if lymphatic contraction can be restored.
MATERIALS AND METHODS
Animals and treatment. All animal research was conducted using protocols approved by the University of Rochester Institutional Animal Care and Use Committee. TNF-transgenic mice (3647 line) (17) were originally acquired from Dr. G. Kollias (Alexander Fleming Institute, Athens, Greece), and were maintained as heterozygotes on a C57BL/6 background. For all imaging, mice were anesthetized with 1.5 -2% isoflurane. Male TNF-transgenic mice (8-10 months old) with collapsed popliteal LNs were treated with anti-TNF (provided by Janssen Pharmaceuticals) or nonspecific IgG1 isotype placebo control monoclonal antibodies (CNTO12 and CNTO151; Janssen) 10 mg/kg per week intraperitoneally, as previously described (6) .
CE-MRI acquisition and analysis. MRI and analysis were performed as previously described (6, 10, 11) . Briefly, TNFtransgenic mice were anesthetized and the knee and ankle were inserted into a customized coil and imaged in a Siemens Trio 3T scanner. After a precontrast scan, 0.5 ml/kg of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) contrast agent (Omniscan; Amersham Health) was injected into the orbital venous plexus. The postcontrast scan was started 5 minutes after injection to allow for circulation of Gd-DTPA.
Histologic analysis. For histologic analysis, mouse knees were harvested and fixed in 10% neutral buffered formalin. The joints were then decalcified in 14% EDTA at room temperature for 21 days. Joints were then embedded in paraffin and cut into 5-mm sections. Sections were deparaffinized and stained with Alcian blue-hematoxylin/orange G, tartrate-resistant acid phosphatase, or F4/80 (AbD Serotec) as previously described (6, 10, 11) .
Power Doppler ultrasound (PDUS). The popliteal LNs of TNF-transgenic mice were phenotyped and classified as collapsed using PDUS as previously described (15) . PDUS was also performed on the mouse knee joints as previously described (18) . Each joint was imaged with a high-resolution small-animal ultrasound system (VisualSonics 770) using a 704b scanhead.
NIR ICG imaging. Mice were placed on a heated surface (Indus Instruments), hair was removed with a depilatory cream, and the footpad was injected with 10 ml of 0.1% ICG (Akorn) as previously described (8) . The imaging system was composed of a lens (Zoom 7000; Navitar), ICG filter set (Semrock), and camera (Prosilica GT1380; Allied Vision Technologies). ICG was excited with a tungsten halogen bulb (IT 9596ER; Illumination Technologies) through a ring illuminator (Schott). Imaging settings and recordings were obtained using a custom-built LabVIEW program (National Instruments). Realtime NIR imaging was performed for 60 minutes after ICG injection into the footpad to quantify the lymphatic contraction frequency, and mice were imaged 24 hours later to quantify percent ICG clearance as previously described (8) .
Flow cytometric analysis. Single-cell suspensions were prepared from LNs by mechanical disruption and stained with a mixture of fluorochrome-conjugated monoclonal antibodies: CD3 (clone 17A2), CD11b (clone M1/70), major histocompatibility complex class II (clone M5/114.15.2), and Gr1 (clone RB6-8C5) (all from BioLegend), CD19 (clone 1D3) and CD11c (clone HL3) (both from BD PharMingen), and F4/80 (BM8; eBioscience), as previously described (13) . All of the samples were stained for dead cell exclusion using a Live/Dead Fixable Violet Dead Cell Stain kit (Invitrogen) and fixed in 1% formaldehyde before running on the instrument. Samples were run on a 12-color LSRII flow cytometer (BD PharMingen) and analyzed using FlowJo software (Tree Star).
Transmission electron microscopy (TEM). The lymphatic vessel afferent to the popliteal LN was identified by injecting Evans blue into the mouse footpad and was then excised and immersion-fixed at 48C using a combination fixative of 2.5% glutaraldehyde and 4.0% paraformaldehyde in 0.1M sodium cacodylate buffer for 24 hours. The specimens were rinsed in 0.1M sodium cacodylate buffer and postfixed with buffered 1% osmium tetroxide. The tissue was dehydrated in a graded series of ethanol to 100%, transitioned into propylene oxide, and infiltrated with Epon-Araldite epoxy resin, followed by embedding in fresh resin and polymerization for 2 days at 608C. To identify the lymphatic vessel in the specimen, the epoxy-embedded block was cut serially into 1m slices and stained with toluidine blue. The lymphatic vessel was then trimmed of excess surrounding tissue and thin sectioned at 70 nm using a diamond knife and ultramicrotome. The thin sections were placed onto Formvar/carbon slot nickel grids and stained with uranyl acetate and lead citrate. A Hitachi 7650 transmission electron microscope with an 11-megapixel Erlangshen digital camera (Gatan) was used to image the grids.
Statistical analysis. Significance was determined by MannWhitney test for non-normally distributed data or t-test for normally distributed data. Normality was tested using a Shapiro-Wilk normality test. Longitudinal data were analyzed using two-way analysis of variance with multiple comparisons corrected for by controlling the false discovery rate or Bonferroni post hoc test. P values less than 0.05 were considered significant. Figures 2E and F) . We also performed PD volume measurements in the mouse knee joint space as an additional assessment of synovial vascularity and 
RESULTS

Consistent
ANTI-TNF RESTORES LYMPHATIC VESSEL CONTRACTIONS
inflammation. After 6 weeks of treatment, a higher PD signal was obvious in the placebo group, compared to the anti-TNF treatment group (Supplementary Figures 2G  and H) . Longitudinally, US showed a dramatic and continual increase in PD volume in the placebo group, while anti-TNF prevented an increase in joint inflammation (Supplementary Figure 2I) .
Longitudinal NIR ICG imaging demonstrated a remarkable increase in lymphatic transport in anti-TNFtreated mice compared to placebo-treated mice, in which ICG uptake was low or absent at 6 weeks ( Figure 1) . Quantification of the frequency of lymphatic contractions confirmed that the anti-TNF effects were due in part to active transport ( Figures 1C and F) , which resulted in increased lymphatic clearance ( Figure 1G) . Notably, anti-TNF-treated mice showed consistent, regular lymphatic contractions that were significantly increased versus placebo-treated mice, and equivalent to findings in wildtype mice (;2 contractions/minute), similar to previous studies (8) . Moreover, this is the first demonstration that lymphatic contractions can be recovered after popliteal LN collapse in this model.
To further dissect the mechanisms of action of anti-TNF therapy, we assessed drug effects on the cellular composition of the popliteal LNs by flow cytometry. The results showed that the increased cellular egress from inflamed joints following anti-TNF treatment was accompanied by higher total cell numbers in the collapsed Figure 2 . Ultrastructural evidence of lymphatic vessel repair and rolling leukocytes in anti-tumor necrosis factor (anti-TNF)-treated TNF-transgenic mice that recovered lymphatic vessel contractions. Wild-type and TNF-transgenic mice (n 5 3 per group) underwent transmission electron microscopy imaging as described in Materials and Methods. Low-magnification imaging was used to identify lymphatic vessels. After the lymphatic vessel was identified, vessel walls were imaged at 10,0003 magnification. A, Representative low-magnification image of lymphatic vessels in a wild-type mouse. Original magnification 3 2,500. B, Representative image of the vessel wall in a wild-type mouse. Note the absence of cells in the lumen (L). C, Representative image of the vessel wall in an untreated TNF-transgenic mouse with expanding popliteal lymph nodes (LNs). Note the activated macrophage (Mf) with initial pseudopod attachment to endothelial cells (EC) afferent to the expanded popliteal LNs. D, Representative image of the vessel wall in an untreated TNF-transgenic mouse with collapsed popliteal LNs. Note the complete macrophage attachment to ECs afferent to collapsed popliteal LNs. E, Representative image of the vessel wall in a placebo (IgG)-treated TNF-transgenic mouse with collapsed popliteal LNs. Note the exacerbated destruction of the lymphatic vessel as evidenced by vacuole formation in ECs (arrows). F, Representative image of the vessel wall in an anti-TNFtreated TNF-transgenic mouse with collapsed popliteal LNs. Note the mononucleated leukocytes that appear to be rolling along the endothelium (asterisks), indicative of restored cellular egress. SMC 5 smooth muscle cell. Original magnification 3 10,000 in B-F.
popliteal LNs of TNF-transgenic mice (Table 1) . Although our cellular subset analysis displayed trends suggesting increased numbers of B cells and T cells in anti-TNFtreated mice, the only significant changes observed in the popliteal LN populations in mice treated with anti-TNF therapy were a 2.1-fold increase in monocyte/macrophages (CD32CD192CD11b1) and a 2.9-fold increase in granulocytes (CD32CD192CD11b1CD11c2F4/802Gr11). Taken together, these findings support a model in which anti-TNF therapy ameliorates synovitis potentially by enhancing cellular egress from the joint via active lymphatic transport through the draining LNs.
To corroborate our finding of anti-TNF-induced monocyte/macrophage egress, we performed TEM on the lymphatic vessels afferent to popliteal LNs. Wild-type mouse lymphatic vessels showed intact lymphatic endothelial and muscle cells (Figures 2A and B) with lumens devoid of cells. Vessels afferent to expanding popliteal LNs showed initial, and what appeared as weak, luminal attachment of large (.5 mm) macrophages to the endothelial cells (Figure 2C ), while vessels afferent to collapsed popliteal LNs showed these activated macrophages firmly attached to the endothelial cells, indicated by the increased surface area of macrophage attachment ( Figure 2D ). TEM images of lymphatic vessels from placebo-treated mice displayed extensive tissue destruction as evidenced by large vacuoles in endothelial cells and degenerated muscle cells ( Figure 2E) . Notably, mice with collapsed popliteal LNs treated with anti-TNF showed evidence of restored cellular egress; TEM revealed small (,2 mm) leukocytes with a rolling cell morphology on the luminal endothelium (Figure 2F ). In particular, we did not observe cytoplasmic vacuoles in endothelial cells, a finding associated with damaged lymphatic vessels, providing additional support to explain the recovery of lymphatic contraction (15) .
DISCUSSION
Advances in drug development over the last 2 decades have provided an array of treatment options in RA (19, 20) . Despite this progress, major unmet clinical needs remain for a significant proportion of RA patients (;40%) who are partial responders, or whose disease is refractory to all currently available therapies including anti-TNF. There is also a larger group of RA patients who experience periodic arthritis flares. Thus, new therapeutic strategies are needed, which requires formal elucidation of the mechanisms of action of drugs currently in use. To this end, we have focused on lymphatic changes during arthritis progression and flare (6, 8, 10, 13, 21) and the effects of interventions that specifically target lymphatic contractions, whose physiologic importance in supporting lymphatic drainage and subsequent onset of lymphedema have been established in preclinical and clinical studies (22, 23) .
It is well known that monocyte/macrophages (type A synoviocytes) are the most abundant cell type in RA inflamed synovium, and that these cells are a major source of inflammatory mediators and catabolic factors in pannus tissue (24) . Moreover, results from RA trials with various drug therapies have shown that clinical efficacy directly correlates with an observed decrease in CD681 synovial sublining macrophages (25, 26) . Many studies have addressed the mechanisms responsible for the reduction in RA monocyte/macrophages in response to anti-TNF treatment, but the findings have been inconclusive and contradictory. For example, while anti-TNFinduced apoptosis of synoviocytes in RA has been reported (27) , other studies failed to show these effects (1, 2) . Other investigations demonstrated that anti-TNF therapy reduced the generation of osteoclasts and bone erosion (28) . In contrast, we found that anti-TNF decreases macrophage/monocyte numbers in the joint by increasing lymphatic transport and potentially cell egress from inflamed joints. These findings are further supported by previous studies demonstrating that anti-TNF therapy increased lymphangiogenesis both in a murine model and in RA patients (4) .
Our data demonstrate that reduction in joint inflammation ( Supplementary Figures 1 and 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40047/abstract) is accompanied by an increase in lymphatic contraction frequency and lymphatic clearance (Figure 1) , and a significant increase in the number of CD11b1 cells in the draining LNs (Table 1) . Previously, we have shown that CD11b1 cells migrate in lymphatic vessels afferent to expanding popliteal LNs, and are immobile within these lymphatic vessels during the popliteal LN collapsed phase (8) . Therefore, the best explanation for the concomitant decrease in myeloid synoviocytes and increased CD11b1 cells in the popliteal LNs after 6 weeks of anti-TNF therapy is increased cell egress through the lymphatic system, as evidenced by the rolling leukocytes in lymphatic vessels ( Figure 2F ). However, important points that were not addressed in the present study include the possibility that CD11b1 cells enter the popliteal LNs through high endothelial venules and a potential increase in T cells and B cells. Therefore, formal histology studies to determine the temporal and spatial increases in distinct myeloid and lymphocytic populations in the popliteal LNs following anti-TNF therapy are planned. It may also be possible to assess increased lymphatic clearance following anti-TNF treatment of RA patients using new NIR ICG imaging methods (21) .
In addition to our studies of anti-TNF treatment of TNF-transgenic mice described here and elsewhere (6,10,11), we have assessed the effects of anti-CD20 in this RA model (8, 13) . Although head-to-head efficacy studies have yet to be performed, there were several general findings that highlight distinct drug mechanisms of action on joint inflammation and lymphatic clearance. The first is that anti-TNF therapy ameliorates arthritis in both ankle and knee joints, while anti-CD20 and genetic B cell depletion affect only knee arthritis (8) . This may be due to anti-TNF effects on both tenosynovitis, which drives ankle arthritis in this model (29) , and knee flare triggered by the loss of lymphatic drainage (Supplementary Figure 1) , while anti-CD20 affects only the latter (8, 13) . Second, anti-CD20 efficacy appears to be due to "unclogging" of lymphatic vessels to restore passive lymphatic flow, as evidenced by a dramatic increase in popliteal LN contrast enhancement on CE-MRI and loss of CD231/CD21 high B cells in inflamed nodes without lymphatic contractions (8) , while anti-TNF targets the underling etiology in this model to decrease inflammation and restore lymphatic contractions (Figure 1 ) without decreasing popliteal LN B cell numbers (Table 1) .
In summary, these data show that in a murine model of arthritis, TNF inhibition is followed by increased lymphatic drainage from the joint, providing a possible clearance mechanism for inflammatory cells. More importantly, we demonstrate for the first time that a therapeutic agent can restore steady normal lymphatic contractions subsequent to arthritic flare associated with collapsed draining LNs and the loss of lymphatic contractions. Thus, drugs specifically designed to facilitate lymphatic vessel repair and return of lymphatic contractions remain intriguing and novel treatments for additional exploration.
